Listing of Claims:

~~1. A method of treating myelofibrosis in a subject comprising administering to the subject a therapeutically effective amount of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt thereof.~~

~~2. The method of Claim 1, wherein the subject has previously undergone treatment with a janus kinase (JAK) inhibitor.~~

~~3. The method of Claim 1 or 2, wherein the subject is progressed/relapsed to a JAK inhibitor.~~

~~4. The method of Claim 1 or 2 wherein the subject is refractory/resistant to a JAK inhibitor.~~

~~5. The method of any one of Claims 1 to 4, wherein the subject has previously undergone treatment with ruxolitinib.~~

~~6. A method of treating myelofibrosis in a subject comprising administering to the subject a therapeutically effective amount of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide and a therapeutically effective amount of a janus kinase (JAK) inhibitor, or a pharmaceutically acceptable salt of any of the foregoing.~~

~~7. The method of Claim 6, wherein the JAK inhibitor is ruxolitinib.~~

~~8. The method of any one of Claims 1 to 7, wherein the subject is cytopenic.~~

~~9. The method of any one of Claims 1 to 8, wherein the subject is anemic.~~

~~10. The method of any one of Claims 1 to 9, wherein the subject has a hemoglobin count of less than 10 g/dL.~~

~~11. The method of any one of Claims 1 to 10, wherein the subject is thrombocytopenic.~~

~~12. The method of any one of Claims 1 to 11, wherein the subject's platelet count is less than 120,000 platelets/μL.~~

~~13. The method of any one of Claims 1 to 10, wherein the subject is thrombocytemic.~~

~~14. The method of any one of Claims 1 to 10 and 13, wherein the subject's platelet count is more than 500,000 platelets/μL.~~

~~15. The method of any one of Claims 1 to 14, wherein the subject is neutropenic.~~

~~16. The method of any one of Claims 1 to 15, wherein the subject's absolute neutrophil count is less than 1000 neutrophils/μL of blood.~~

~~17. The method of any one of Claims 1 to 16, wherein the subject has an enlarged spleen or liver.~~

~~18. The method of any one of Claims 1 to 17, wherein the subject is suffering from abdominal discomfort, dyspnea on exertion, early satiety, fatigue, headaches, night sweats, dizziness, insomnia, pruritus, or bone pain.~~

~~19. The method of any one of Claims 1 to 18, wherein the subject is transfusion dependent.~~

~~20. The method of any one of Claims 1 to 5 and 8 to 19, wherein the subject is administered from 100 mg/day to 300 mg/day of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt thereof.~~

~~21. The method of any one of Claims 1 to 5 and 8 to 20, wherein the subject is administered from 150 mg/day to 250 mg/day of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt thereof.~~

~~22. The method of any one of Claims 6 to 19, wherein the subject is administered from 100 mg/day to 300 mg/day of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt thereof.~~

~~23. The method of any one of Claims 6 to 19 and 22, wherein the subject is administered from 100 mg/day to 200 mg/day of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt thereof.~~

~~24. The method of any one of Claims 1 to 23, wherein the subject is administered 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt thereof, once per day.~~

1. Use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating myelofibrosis.

2. The use of Claim 1, wherein the subject has previously undergone treatment with a janus kinase (JAK) inhibitor.

3. The use of Claim 1 or Claim 2, wherein the subject is progressed/relapsed to a JAK inhibitor.

4. The use of any one of Claims 1 to 3, wherein the subject is refractory/resistant to a JAK inhibitor.

5. The use of any one of Claims 1 to 4, wherein the subject has previously undergone treatment with ruxolitinib.

6. Use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide and a janus kinase (JAK) inhibitor, or a pharmaceutically acceptable salt of any of the foregoing, in the manufacture of a medicament for treating myelofibrosis.

7. Use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a

medicament for treating myelofibrosis, the medicament being formulated for administration with a janus kinase (JAK) inhibitor.

8. The use of Claim 6 or 7, wherein the JAK inhibitor is ruxolitinib.

9. The use of any one of Claims 1 to 8, wherein the subject is cytopenic.

10. The use of any one of Claims 1 to 9, wherein the subject is anemic.

11. The method or the use of any one of Claims 1 to 10, wherein the subject has a hemoglobin count of less than 10 g/dL.

12. The use of any one of Claims 1 to 11, wherein the subject is thrombocytopenic.

13. The use of any one of Claims 1 to 12, wherein the subject's platelet count is less than 120,000 platelets/μL.

14. The method or the use of any one of Claims 1 to 11, wherein the subject is thrombocytemic.

15. The use of any one of Claims 1 to 11 and 14, wherein the subject's platelet count is more than 500,000 platelets/μL.

16. The use of any one of Claims 1 to 15, wherein the subject is neutropenic.

17. The use of any one of Claims 1 to 16, wherein the subject's absolute neutrophil count is less than 1000 neutrophils/μL of blood.

18. The use of any one of Claims 1 to 17, wherein the subject has an enlarged spleen or liver.

19. The use of any one of Claims 1 to 18, wherein the subject is suffering from abdominal discomfort, dyspnea on exertion, early satiety, fatigue, headaches, night sweats, dizziness, insomnia, pruritus, or bone pain.

20. The use of any one of Claims 1 to 19, wherein the subject is transfusion dependent.

21. The use of any one of Claims 1 to 5 and 9 to 20, wherein the medicament is formulated for administration of 100 mg/day to 300 mg/day of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt thereof.

22. The use of any one of Claims 1 to 5 and 9 to 21, wherein the medicament is formulated for administration of 150 mg/day to 250 mg/day of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt thereof.

23. The use of any one of Claims 6 to 20, wherein the medicament is formulated for administration of 100 mg/day to 300 mg/day of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt thereof.

24. The use of any one of Claims 6 to 20 and 23, wherein the medicament is formulated for administration of 100 mg/day to 200 mg/day of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt thereof.

25. The use of any one of Claims 1 to 24, wherein the medicament is formulated for administration of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt thereof, once per day.